New therapies for hemophilia, Blood, vol.133, issue.5, pp.389-398, 2019. ,
Emerging Therapeutic Strategies in the Treatment of Hemophilia A, Semin Thromb Hemost, vol.43, issue.6, pp.581-590, 2017. ,
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model, Nat Med, vol.18, issue.10, pp.1570-1574, 2012. ,
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens, Thromb Haemost, vol.117, issue.7, pp.1348-1357, 2017. ,
Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?, Blood, vol.130, issue.23, pp.2463-2468, 2017. ,
Emicizumab Prophylaxis in Hemophilia A with Inhibitors, N Engl J Med, vol.377, issue.9, pp.809-818, 2017. ,
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors, N Engl J Med, vol.379, issue.9, pp.811-822, 2018. ,
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study, Lancet Haematol, vol.6, issue.6, pp.295-305, 2019. ,
A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors, Blood, 2019. ,
Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence, J Thromb Haemost, vol.17, issue.7, pp.1044-1052, 2019. ,
Assay challenges (and opportunities) with non-factor VIII therapies for Hemophilia A, Expert Rev Mol Diagn, vol.19, issue.1, pp.1-3, 2019. ,
In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents, J Thromb Haemost, 2018. ,
Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab, Haematologica, vol.103, issue.4, pp.181-183, 2018. ,
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A, Nat Genet, vol.10, issue.1, pp.119-121, 1995. ,
The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiology of haemostasis and thrombosis, vol.32, pp.249-253, 2002. ,
, Effects and Interferences of Emicizumab
, Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays, Thromb Haemost, vol.119, issue.7, pp.1084-1093, 2019.
Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo, Blood, vol.100, issue.1, pp.153-158, 2002. ,
A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A, Thromb Haemost, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02570572
Development of the human coagulation system in the full-term infant, Blood, vol.70, issue.1, pp.165-172, 1987. ,
Development of the human coagulation system in the healthy premature infant, Blood, vol.72, issue.5, pp.1651-1657, 1988. ,
Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice, Blood, vol.128, issue.2, pp.286-292, 2016. ,
An inducible mouse model of factor X deficiency to test novel factor X therapeutics. Research and Practice in Thrombosis and Haemostasis, vol.3, 2019. ,
A novel humanized hemophilia-a mouse model to facilitate preclinical in vivo studies of human specific FVIIIa-mimetic bispecific antibodies, Blood, vol.132, 2018. ,